Clinical Trial Results:
A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and GSK Biologicals measles-mumps-rubella vaccine Priorix co-administered in separate injections with GSK Biologicals varicella vaccine Varilrix when given in healthy children who previously received a first dose of an MMR vaccine and one dose of a varicella vaccine.
Summary
|
|
EudraCT number |
2005-005825-75 |
Trial protocol |
IT |
Global completion date |
03 Nov 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
Yes
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Apr 2019
|
First version publication date |
10 Apr 2019
|
Other versions |
|
Summary report(s) |
105909-Clinical-Study-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.